BioNTech SE Share Price BOERSE MUENCHEN

Equities

22UA

US09075V1026

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN 17:05:11 21/05/2024 BST 5-day change 1st Jan Change
83.95 EUR -0.18% Intraday chart for BioNTech SE -2.10% -11.60%

Financials

Sales 2024 * 2.8B 3.04B 239B Sales 2025 * 2.77B 3B 236B Capitalization 20.55B 22.3B 1,755B
Net income 2024 * -415M -451M -35.45B Net income 2025 * -491M -533M -41.94B EV / Sales 2024 * 2.06 x
Net cash position 2024 * 14.78B 16.04B 1,262B Net cash position 2025 * 13.76B 14.94B 1,176B EV / Sales 2025 * 2.45 x
P/E ratio 2024 *
-49 x
P/E ratio 2025 *
-43.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 week-2.10%
Current month+1.26%
1 month+2.56%
3 months-0.47%
6 months-6.82%
Current year-11.60%
More quotes
1 week
83.05
Extreme 83.05
86.05
1 month
80.15
Extreme 80.15
88.15
3 years
78.70
Extreme 78.7
397.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 01/06/08
Founder 57 01/06/08
Director of Finance/CFO 60 30/06/21
Members of the board TitleAgeSince
Director/Board Member 69 31/12/21
Director/Board Member 67 01/06/08
Chairman 53 01/06/08
More insiders
Date Price Change
21/05/24 83.95 -0.18%
20/05/24 84.1 +0.90%
17/05/24 83.35 -2.51%
16/05/24 85.5 +1.00%
15/05/24 84.65 -0.41%

Real-time BOERSE MUENCHEN, May 21, 2024 at 05:05 pm

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
85.14 EUR
Average target price
105.4 EUR
Spread / Average Target
+23.78%
Consensus